In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer

Journal of Clinical Investigation

Volumn 115, Issue 8, 2005, Pages 2287-2295

  Adjali, Oumeya ^a   Marodon, Gilles ^b   Steinberg, Marcos ^a   Mongellaz, Cédric ^a   Thomas Vaslin, Véronique ^b   Jacquet, Chantal ^a   Taylor, Naomi ^a   Klatzmann, David ^b,c  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; LENTIVIRUS VECTOR; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADOLESCENT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL REGENERATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DNA MODIFICATION; EX VIVO STUDY; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THYMUS;

ANIMALS; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; LYMPHOPOIESIS; MICE; MICE, KNOCKOUT; PROTEIN-TYROSINE KINASES; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES; THYMUS GLAND; TRANSDUCTION, GENETIC; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 23644459829     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23966     Document Type: Article

References (45)

1. Antoine, C., et al. 2003. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 361:553-560.
2. Buckley, R.H., et al. 1999. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340:508-516.
3. Patel, D.D., et al. 2000. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 342:1325-1332.
4. Kohn, D.B., et al. 1998. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA- deficient SCID neonates. Nat. Med. 4:775-780.
5. Cavazzana-Calvo, M., et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:669-672.
6. Aiuti, A., et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2410-2413.
7. Gaspar, H.B., et al. 2004, Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 364:2181-2187.
8. Hitschhorn, R., et al. 1996. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 13:290-295.
9. Bousso, P., et al. 2000. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl. Acad. Sci. U. S. A. 97:274-278.
10. Stephan, V., et al. 1996. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335:1563-1567.
11. Ariga, T., et al. 2001. T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood. 97:2896-2899.
12. Cavazzana-Calvo, M., et al. 1999. Correction of SCID-XI disease phenotype following gc gene transfer by a retroviral vector into CD34+ cells in two children [abstract]. Blood. 94(Suppl. 1):367a.
13. Fischer, A., Hacein-Bey, S., and Cavazzana-Calvo, M. 2002. Gene therapy of severe combined immunodeficiencies. Nat. Rev. Immunol. 2:615-621.
14. Hacein-Bey-Abina, S., et al. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-256.
15. Li, Z., et al. 2002. Murine leukemia induced by retroviral gene marking. Science. 296:497.
16. Esslinger, C., et al. 2003. In vivo administration of a lentiviral vaccine Targets DCs and induces efficient CD8(+) T cell responses. J. Clin. Invest. 111:1673-1681. doi:10.1172/JCI200317098.
17. VandenDriessche, T., et al. 2002. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood. 100:813-822.
18. Yanay, O., et al. 2003, Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery. Blood. 102:2046-2052.
19. Palmowski, M., Salio, M., Dunbar, R.P., and Cerundolo, V. 2002. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol. Rev. 188:155-163.
20. Kobinger, G.P., Louboutin, J.P., Barton, E.R., Sweeney, H.L., and Wilson, J.M. 2003. Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum. Gene Ther. 14:1441-1449.
21. Baekelandt, V., Eggermont, K., Michiels, M., Nuttin, B., and Debyser, Z. 2003. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 10:1933-1940.
22. Marodon, G., and Klatzmann, D. 2004. In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors. BMC Immunol. 5:18.
23. Allman, D., et al. 2003. Thymopoiesis independent of common lymphoid progenitors. Nat. Immunol. 4:168-174.
24. Chan, A.C., Iwashima, M., Turck, C.W., and Weiss, A. 1992. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 71:649-662.
25. Chan, A.C., et al. 1994. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J. Immunol. 152:4758-4766,
26. Negishi, I., et al. 1995. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature. 376:435-438.
27. Wiest, D.L., et al. 1997. A spontaneously arising mutation in the DLAARN motif of murine ZAP-70 abrogates kinase activity and arrests thymocyte development. Immunity. 6:663-671.
28. Kadlecek, T.A., et al. 1998. Differential requirements for ZAP-70 in TCR signaling and T cell development. J. Immunol 161:4688-4694.
29. Marodon, G., et al. 2003. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4gene. Blood. 101:3416-3423.
30. Porritt, H.E., Gordon, K., and Petrie, H.T. 2003. Kinetics of steady-state differentiation and mapping of intrathymic-signaling environments by stem cell transplantation in nonirradiated mice. J. Exp. Med. 198:957-962.
31. Otsu, M., et al. 2002. Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells. Blood. 100:1248-1256.
32. Bellier, B., Thomas-Vaslin, V., Saron, M.F., and Klatzmann, D. 2003. Turning immunological memory into amnesia by depletion of dividing T cells. Proc. Natl. Acad. Sci. U. S. A. 100:15017-15022,
33. Puisieux, I., et al. l 996. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int. J. Cancer. 66:201-208.
34. Pannetier, C., Even, J., and Kourilsky, P. 1995. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol. Today. 16:176-181.
35. Williams, B.L., et al. 1998. Genetic evidence for differential coupling of Syk family kinases to the T-cell receptor: reconstitution studies in a ZAP-70-deficient Jurkat T-cell line. Mol. Cell. Biol. 18:1388-1399.
36. Unutmaz, D., KewalRamani, V.N., Marmon, S., and Littman, D.R. 1999. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-1746.
37. Hirschhorn, R. 2003. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 40:721-728.
38. Lo, M., et al. 1999. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood. 94:3027-3036.
39. Otsu, M., et al. 2000. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol. Ther. 1:145-153.
40. Steinberg, M., et al. 2000. Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy. Gene Ther. 7:1392-1400.
41. Yee, J.K., et al. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 91:9564-9568.
42. Dardalhon, V., et al. 2001. IL-7 differentially regulates cell cycle progression and HIV-1-based vector infection in neonatal and adult CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A. 98:9277-9282.
43. Pannetier, C., et al. 1993. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc. Natl. Acad. Sci. U. S. A. 90:4319-4323.
44. Cochet, M., et al. 1992. Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur. J. Immunol. 22:2639-2647.
45. Arden, B., Clark, S.P., Kabelitz, D., and Mak, T.W. 1995. Human T-cell receptor variable gene segment families. Immunogenetics. 42:455-500.